OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for RC200395L2V

Apolipoprotein E (APOE) (NM_000041) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Product Name:	Apolipoprotein E (APOE) (NM_000041) Human Tagged ORF Clone Lentiviral Particle
Symbol:	APOE
Synonyms:	AD2; APO-E; ApoE4; LDLCQ5; LPG
Mammalian Cell Selection:	None
Vector:	pLenti-C-mGFP (PS100071)
Tag:	mGFP
ACCN:	NM_000041
ORF Size:	951 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC200395).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	NM_000041.2
RefSeq Size:	1223 bp
RefSeq ORF:	954 bp
Locus ID:	348
UniProt ID:	P02649
Cytogenetics:	19q13.32
Domains:	Apolipoprotein
Protein Families:	Adult stem cells, Druggable Genome, Secreted Protein, Stem cell - Pluripotency

View online »

Protein Pathways: Alzheimer's disease

MW: 36.2 kDa

Gene Summary: The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]